Global Orphan Drugs Market 2021

January 2022 | 18 pages | ID: G0884DF6307DEN
StrategyHelix Inc

Abstracts

An orphan drug is a medicine for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition that is rare or where the medicine is unlikely to generate sufficient profit to justify research and development costs. They are orphans because the pharmaceutical industry has little interest under normal market conditions in developing and marketing drugs intended for only a small number of patients suffering from very rare conditions. The global orphan drugs market is poised to grow by US$ 68,701 million from 2021 to 2027, registering a CAGR of 5.5% during the forecast period, according to StrategyHelix. Availability of exclusivity for orphan drugs, rising prevalence of rare diseases, favorable government policies are expected to boost the market growth in the coming years.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for orphan drugs. The global orphan drugs market is segmented on the basis of drug type, top selling drug, disease type, and region. By drug type, the global orphan drugs market has been segmented into biological drugs, non-biological drugs. According to the research, the biological drugs segment had the largest share in the global orphan drugs market. Based upon top selling drug, the global orphan drugs market is categorized into Revlimid, Tafinlar, Hemlibra, Darzalex, Kyprolis, Myozyme, Vyndaqel, Soliris, Ninlaro, Imbruvica, others. In 2020, the Revlimid segment made up the largest share of revenue generated by the orphan drugs market. On the basis of disease type, the global orphan drugs market has been segmented into oncology, blood disorders, central nervous system, respiratory system, immunomodulators, cardiovascular therapies, others. Among these, the oncology segment was accounted for the highest revenue generator in 2020. In terms of geography, the global orphan drugs market has been segmented into North America, Asia Pacific, Europe, Rest of the World (ROW).

The global orphan drugs market is highly competitive. As of 2020, the major players in the global orphan drugs market were AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen Inc., AstraZeneca plc, Biogen Inc., BioMarin Pharmaceutical Inc., Bristol-Myers Squibb Company, Celgene Corporation, CSL Behring GmbH, Eisai Co. Ltd., F. Hoffmann-La Roche AG, Incyte Corporation, Jiangsu Hengrui Medicine Co. Ltd., Johnson & Johnson, Novartis AG, Pfizer Inc., Sanofi S.A., Syros Pharmaceuticals Inc., Takeda Pharmaceutical Company Ltd., Vertex Pharmaceuticals Inc.

Report Scope
Drug type: biological drugs, non-biological drugs
Top selling drug: Revlimid, Tafinlar, Hemlibra, Darzalex, Kyprolis, Myozyme, Vyndaqel, Soliris, Ninlaro, Imbruvica, others
Disease type: oncology, blood disorders, central nervous system, respiratory system, immunomodulators, cardiovascular therapies, others
Region: North America, Asia Pacific, Europe, Rest of the World (ROW)
Years considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders
Get a comprehensive picture of the global orphan drugs market
Pinpoint growth sectors and trends for investment

Contents

PART 1. INTRODUCTION

Scope of the study
Study period
Geographical scope
Research methodology

PART 2. ORPHAN DRUGS MARKET OVERVIEW

PART 3. MARKET BREAKDOWN BY DRUG TYPE

Biological drugs
Non-biological drugs

PART 4. MARKET BREAKDOWN BY TOP SELLING DRUG

Revlimid
Tafinlar
Hemlibra
Darzalex
Kyprolis
Myozyme
Vyndaqel
Soliris
Ninlaro
Imbruvica
Others

PART 5. MARKET BREAKDOWN BY DISEASE TYPE

Oncology
Blood disorders
Central nervous system
Respiratory system
Immunomodulators
Cardiovascular therapies
Others

PART 6. MARKET BREAKDOWN BY REGION

North America
Asia Pacific
Europe
Rest of the World (ROW)

PART 7. KEY COMPANIES

AbbVie Inc.
Alexion Pharmaceuticals Inc.
Amgen Inc.
AstraZeneca plc
Biogen Inc.
BioMarin Pharmaceutical Inc.
Bristol-Myers Squibb Company
Celgene Corporation
CSL Behring GmbH
Eisai Co., Ltd.
F. Hoffmann-La Roche AG
Incyte Corporation
Jiangsu Hengrui Medicine Co., Ltd.
Johnson & Johnson
Novartis AG
Pfizer Inc.
Sanofi S.A.
Syros Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Ltd.
Vertex Pharmaceuticals, Inc.
About StrategyHelix
Disclaimer